Atenolol (versus unexposed) updated on 12-17-2024

Preterm (< 37 weeks)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S14363
R56867		 Orbach, 2013 Preterm delivery (< 37 weeks of gestation) 3rd trimester retrospective cohort (claims database) unexposed, disease free Adjustment: Yes Indications Antihypertensive: All hypertensions, any indications or not specified 2.68 [1.57;4.56] 18/107   7,836/97,820 7,854 107
ref
S14298
R56328		 Lydakis, 1999 Delivery <37 Weeks during pregnancy (anytime or not specified) retrospective cohort unexposed, sick Adjustment: No Indications Antihypertensive: Only chronic hypertension indication 2.75 [1.31;5.76] C 26/78   14/91 40 78
ref
Total 2 studies 2.70 [1.75;4.17] 7,894 185
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Orbach, 2013Orbach, 2013 2.68[1.57; 4.56]7,85410766%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Lydakis, 1999Lydakis, 1999 2.75[1.31; 5.76]407834%ROB confusion: seriousROB selection: moderateROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 0% 2.70[1.75; 4.17]7,8941850.910.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 2.70[1.75; 4.17]7,8941850%NAOrbach, 2013 Lydakis, 1999 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 2.68[1.57; 4.57]7,854107 -NAOrbach, 2013 1 unexposed, sickunexposed, sick 2.75[1.31; 5.76]4078 -NALydakis, 1999 1 Tags Adjustment   - No  - No 2.75[1.31; 5.76]4078 -NALydakis, 1999 1   - Yes  - Yes 2.68[1.57; 4.57]7,854107 -NAOrbach, 2013 1 Indications Antihypertensive   - All hypertensions, any indications ...  - All hypertensions, any indications or not specified 2.68[1.57; 4.57]7,854107 -NAOrbach, 2013 1   - Only chronic hypertension indication  - Only chronic hypertension indication 2.75[1.31; 5.76]4078 -NALydakis, 1999 1 All studiesAll studies 2.70[1.75; 4.17]7,8941850%NAOrbach, 2013 Lydakis, 1999 20.510.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 2.68[1.57; 4.57]7,854107 -NAOrbach, 2013 1 unexposed, sick controlsunexposed, sick controls 2.75[1.31; 5.76]4078 -NALydakis, 1999 10.510.01.0

Umbrella review (other published meta-analyses)

Published MAControlPeriodTE95% CIn exposedkI2 Bellos (Preterm birth (Randomized controlled ...Bellos (Preterm birth (Randomized controlled trial and Cohort studies)) 1.30[0.43; 3.92]NA-U,Sunexposed, sickAnyduring pregnancy (anytime or not specified)studies TTT-9 metaPregmetaPreg 2.70[1.75; 4.17]0%185----Orbach, 2013 Lydakis, 1999 20.510.01.0